Publication | Open Access

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

Liposomal Doxorubicin HclMetastatic Breast CancerOncologyBreast OncologyPharmacologyPhase IiitrialBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentMedicine